ScienceGate
Advanced Search
Author Search
Journal Finder
Blog
Sign in / Sign up
ScienceGate
Search
Author Search
Journal Finder
Blog
Sign in / Sign up
The Protective Effect of Zoledronic Acid on Bone Loss in Postmenopausal Women with Early Breast Cancer Treated with Sequential Tamoxifen and Letrozole: A Prospective, Randomized, Phase II Trial
Oncology
◽
10.1159/000334456
◽
2011
◽
Vol 81
(5-6)
◽
pp. 298-305
◽
Cited By ~ 12
Author(s):
Tamar Safra
◽
Rinat Bernstein-Molho
◽
Julia Greenberg
◽
Sharon Pelles-Avraham
◽
Irina Stephansky
◽
...
Keyword(s):
Breast Cancer
◽
Zoledronic Acid
◽
Bone Loss
◽
Protective Effect
◽
Postmenopausal Women
◽
Early Breast Cancer
◽
Phase Ii
◽
Phase Ii Trial
◽
Randomized Phase Ii
Download Full-text
Related Documents
Cited By
References
The protective effect of zoledronic acid on bone loss in postmenopausal women with early breast cancer treated with sequential tamoxifen and letrozole: 36-month follow-up.
Journal of Clinical Oncology
◽
10.1200/jco.2011.29.15_suppl.e11111
◽
2011
◽
Vol 29
(15_suppl)
◽
pp. e11111-e11111
◽
Cited By ~ 1
Author(s):
J. Greenberg
◽
S. M. Stemmer
◽
R. Bernstein-Molho
◽
S. Pelles-Avraham
◽
I. Stephansky
◽
...
Keyword(s):
Breast Cancer
◽
Zoledronic Acid
◽
Bone Loss
◽
Protective Effect
◽
Postmenopausal Women
◽
Early Breast Cancer
Download Full-text
0159 Zoledronic acid protective effect on bone loss in postmenopausal women with early breast cancer switched from tamoxifen to letrozole
The Breast
◽
10.1016/s0960-9776(09)70190-0
◽
2009
◽
Vol 18
◽
pp. S60
Author(s):
T. Safra
◽
R. Bernstein Molho
◽
I. Stephansky
◽
N. Yaal-Hahoshen
◽
M. Inbar
◽
...
Keyword(s):
Breast Cancer
◽
Zoledronic Acid
◽
Bone Loss
◽
Protective Effect
◽
Postmenopausal Women
◽
Early Breast Cancer
Download Full-text
Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a randomized phase II trial
Annals of Oncology
◽
10.1093/annonc/mdy211
◽
2018
◽
Vol 29
(8)
◽
pp. 1777-1783
◽
Cited By ~ 26
Author(s):
M. Ignatiadis
◽
S. Litière
◽
F. Rothe
◽
S. Riethdorf
◽
C. Proudhon
◽
...
Keyword(s):
Breast Cancer
◽
Tumor Cells
◽
Circulating Tumor Cells
◽
Early Breast Cancer
◽
Phase Ii
◽
Phase Ii Trial
◽
Randomized Phase Ii
Download Full-text
2008 POSTER The E-ZO-FAST trial: Zoledronic acid (ZA) effectively inhibits aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (EBC) receiving adjuvant Letrozole (Let)
European Journal of Cancer Supplements
◽
10.1016/s1359-6349(07)70770-x
◽
2007
◽
Vol 5
(4)
◽
pp. 186-187
◽
Cited By ~ 21
Author(s):
N. Schenk
◽
A. Lombart
◽
A. Frassoladti
◽
P. Neven
◽
G. Jerusalem
◽
...
Keyword(s):
Breast Cancer
◽
Zoledronic Acid
◽
Bone Loss
◽
Aromatase Inhibitor
◽
Postmenopausal Women
◽
Early Breast Cancer
Download Full-text
The effect of zoledronic acid on aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36 months follow-up of ZO-FAST.
10.1158/0008-5472.sabcs-44
◽
2009
◽
Cited By ~ 21
Author(s):
H Eidtmann
◽
NJ Bundred
◽
R DeBoer
◽
A Llombart
◽
N Davidson
◽
...
Keyword(s):
Breast Cancer
◽
Zoledronic Acid
◽
Bone Loss
◽
Aromatase Inhibitor
◽
Postmenopausal Women
◽
Early Breast Cancer
Download Full-text
The Effect of Zoledronic Acid on Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole: The Z-FAST Study 5-Year Final Follow-Up.
10.1158/0008-5472.sabcs-09-4083
◽
2009
◽
Cited By ~ 11
Author(s):
A. Brufsky
◽
G. Harker
◽
J. Beck
◽
R. Carroll
◽
L. Jin
◽
...
Keyword(s):
Breast Cancer
◽
Zoledronic Acid
◽
Bone Loss
◽
Aromatase Inhibitor
◽
Postmenopausal Women
◽
Early Breast Cancer
Download Full-text
LBA19 GEICAM/2014-12 (FLIPPER) study: First analysis from a randomized phase II trial of fulvestrant (F)/palbociclib (P) versus (vs) F/placebo (PL) as first-line therapy in postmenopausal women with HR (hormone receptor)+/HER2– endocrine sensitive advanced breast cancer (ABC)
Annals of Oncology
◽
10.1016/j.annonc.2020.08.2247
◽
2020
◽
Vol 31
◽
pp. S1151
Author(s):
J. Albanell
◽
M.T.M. Martinez
◽
M. Ramos
◽
M.O.' Connor
◽
L. De la Cruz-Merino
◽
...
Keyword(s):
Breast Cancer
◽
Advanced Breast Cancer
◽
Postmenopausal Women
◽
Phase Ii
◽
Hormone Receptor
◽
Phase Ii Trial
◽
First Line
◽
First Line Therapy
◽
Line Therapy
◽
Randomized Phase Ii
Download Full-text
A randomized phase II trial of doxorubicin plus pemetrexed followed by docetaxel versus doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant treatment of early breast cancer
Annals of Oncology
◽
10.1093/annonc/mdq400
◽
2011
◽
Vol 22
(3)
◽
pp. 609-617
◽
Cited By ~ 10
Author(s):
A. Schneeweiss
◽
F. Marmé
◽
A. Ruiz
◽
A.G. Manikhas
◽
A. Bottini
◽
...
Keyword(s):
Breast Cancer
◽
Early Breast Cancer
◽
Phase Ii
◽
Phase Ii Trial
◽
Neoadjuvant Treatment
◽
Randomized Phase Ii
Download Full-text
FemZone trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients
BMC Cancer
◽
10.1186/1471-2407-14-66
◽
2014
◽
Vol 14
(1)
◽
Cited By ~ 13
Author(s):
Peter A Fasching
◽
Sebastian M Jud
◽
Maik Hauschild
◽
Sherko Kümmel
◽
Martin Schütte
◽
...
Keyword(s):
Breast Cancer
◽
Zoledronic Acid
◽
Cancer Patients
◽
Phase Ii
◽
Primary Breast Cancer
◽
Phase Ii Trial
◽
Breast Cancer Patients
◽
Randomized Phase Ii
Download Full-text
Zoledronic acid (ZA) effectively inhibits cancer treatment-induced bone loss (CTIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant letrozole (Let): 12 mos BMD results of the Z-FAST trial
Journal of Clinical Oncology
◽
10.1200/jco.2005.23.16_suppl.533
◽
2005
◽
Vol 23
(16_suppl)
◽
pp. 533-533
◽
Cited By ~ 22
Author(s):
A. Brufsky
◽
W. G. Harker
◽
J. T. Beck
◽
R. Carroll
◽
E. Tan-Chiu
◽
...
Keyword(s):
Breast Cancer
◽
Zoledronic Acid
◽
Bone Loss
◽
Cancer Treatment
◽
Postmenopausal Women
◽
Early Breast Cancer
Download Full-text
Sign in / Sign up
Close
Export Citation Format
Close
Share Document
Close